PNT
POINT Biopharma Global Inc. Common Stock
Delisted
PNT was delisted on the 26th of December, 2023.
About: POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Employees: 129
Financial journalist opinion
Neutral
PRNewsWire
1 year ago
Lilly Completes Acquisition of POINT Biopharma
INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly.
Positive
Market Watch
1 year ago
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.
Negative
Market Watch
1 year ago
Lantheus and Point Biopharma shares drop on prostate cancer treatment data
Shares of Lantheus Holdings Inc. LNTH, -2.38% and Point Biopharma Global Inc. PNT, +2.26% fell sharply premarket on Monday after the companies released new data from a trial of their experimental treatment for prostate cancer. The therapy, Lu-PNT2002, met the trial's primary goal, with a median progression-free survival of 9.5 months, compared with six months for patients on an alternative treatment, an androgen receptor pathway inhibitor, the companies said in a release.
Neutral
GlobeNewsWire
1 year ago
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)
Neutral
PRNewsWire
1 year ago
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.
Positive
Zacks Investment Research
1 year ago
POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know
POINT Biopharma Global Inc. (PNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Reuters
1 year ago
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the radiopharma developer.
Neutral
PRNewsWire
1 year ago
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.
Negative
Reuters
1 year ago
Eli Lilly extends tender offer to buy Point Biopharma after low participation
Eli Lilly on Friday extended the deadline for Point Biopharma Global shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation.
Neutral
PRNewsWire
1 year ago
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.
Charts implemented using Lightweight Charts™